SKYE Skye Bioscience, Inc.
Price Chart
Executive Summary
Skye Bioscience reported Q4 and full-year 2025 financial results, highlighting ongoing clinical progress with its obesity candidate nimacimab, including initiation of a higher-dose expansion study and FDA feedback shaping Phase 2b design. The company emphasized strong combination data with semaglutide, showing 22.3% mean weight loss at 52 weeks and favorable body composition outcomes, but reported a significant net loss increase due to higher R&D and manufacturing costs. Cash runway is expected through Q4 2026, excluding Phase 2b clinical costs.
Key Financial Metrics
Actionable Insight
The strong clinical data supports potential differentiation for nimacimab in combination with incretin therapies, but the significant increase in cash burn raises concerns about future dilution risk. Traders should monitor Q4 2026 topline data from the higher-dose expansion study and finalization of the Phase 2b protocol as key catalysts.
Key Facts
- Initiated higher-dose CBeyond Expansion Study (Part C) with 400 mg and 600 mg IV cohorts to assess safety and pharmacokinetics; topline data expected Q4 2026.
- Received FDA Type C meeting feedback informing Phase 2b combination trial design with incretin therapy.
- Interim 52-week data: 22.3% weight loss with nimacimab + semaglutide, no plateau observed, strong safety profile maintained.
- 13-week off-treatment follow-up: combination cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone; maintained fat loss and gained lean mass.
- Q4 2025 R&D expenses: $11.5M (up from $7.8M in Q4 2024); full-year R&D: $42.4M (vs. $18.7M in 2024).
- Net loss for 2025: $55.9M (vs. $26.6M in 2024), driven by $20.7M increase in contract manufacturing costs.
- Cash, cash equivalents, and short-term investments: $25.7M as of December 31, 2025; expected to fund operations through Q4 2026, excluding Phase 2b clinical costs.
Financial Impact
Net loss nearly doubled year-over-year to $55.9M, primarily due to $20.7M increase in manufacturing costs for Phase 2a extension and anticipated Phase 2b supply. R&D spending more than doubled from 2024 to 2025.
Risk Factors
- High cash burn may necessitate future equity financing, leading to shareholder dilution.
- Phase 2b trial design and dosing strategy remain undefined; regulatory path could be delayed.
- Competitive risk from other obesity therapies in development with more advanced clinical data.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253294 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
5d ago
|
8-K
| $0.8217 awaiting T+5 | awaiting T+5 | — | $0.7690 (+6.41%) |
|
May 12, 2026
8d ago
|
Press Release
| $0.8140 $0.7780 | ▲ +4.42% | ▲ +4.50% | $0.7690 (+5.53%) |
|
Apr 29, 2026
21d ago
|
3
| — | awaiting T+5 | — | — |
|
Apr 16, 2026
4w ago
|
DEFA14A
| $0.7500 $0.8990 | ▲ +19.87% | ▲ +18.88% | $0.7690 (+2.53%) |
|
Apr 2, 2026
6w ago
|
Press Release
| $0.6980 $0.7200 | ▲ +3.15% | ▼ −0.47% | $0.7690 (+10.17%) |
|
Mar 10, 2026
10w ago
|
Press Release
| $0.7210 $0.6730 | ▼ −6.66% | ▼ −4.47% | $0.7690 (+6.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access